Literature DB >> 19506812

Bevacizumab in adult malignant brainstem gliomas.

Shahzad Raza1,2, Martin Donach3.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19506812     DOI: 10.1007/s11060-009-9933-1

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


× No keyword cloud information.
  7 in total

1.  Brainstem gliomas in adults: prognostic factors and classification.

Authors:  J S Guillamo; A Monjour; L Taillandier; B Devaux; P Varlet; C Haie-Meder; G L Defer; P Maison; J J Mazeron; P Cornu; J Y Delattre
Journal:  Brain       Date:  2001-12       Impact factor: 13.501

2.  Natural history and management of brainstem gliomas in adults. A retrospective Italian study.

Authors:  A Salmaggi; L Fariselli; I Milanesi; E Lamperti; A Silvani; A Bizzi; E Maccagnano; E Trevisan; E Laguzzi; R Rudà; A Boiardi; R Soffietti
Journal:  J Neurol       Date:  2008-02-25       Impact factor: 4.849

3.  Feasibility of using bevacizumab with radiation therapy and temozolomide in newly diagnosed high-grade glioma.

Authors:  Ashwatha Narayana; John G Golfinos; Ingeborg Fischer; Shahzad Raza; Patrick Kelly; Erik Parker; Edmond A Knopp; Praveen Medabalmi; David Zagzag; Patricia Eagan; Michael L Gruber
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-10-01       Impact factor: 7.038

4.  Prognostic factors in adult brainstem gliomas: a multicenter, retrospective analysis of 101 cases.

Authors:  Santosh Kesari; Ryung S Kim; Vassilios Markos; Jan Drappatz; Patrick Y Wen; Amy A Pruitt
Journal:  J Neurooncol       Date:  2008-06       Impact factor: 4.130

5.  Adult brainstem gliomas.

Authors:  J C Landolfi; H T Thaler; L M DeAngelis
Journal:  Neurology       Date:  1998-10       Impact factor: 9.910

6.  Bevacizumab and irinotecan treatment for progressive diffuse brainstem glioma: case report.

Authors:  Roy Torcuator; Richard Zuniga; Randa Loutfi; Tom Mikkelsen
Journal:  J Neurooncol       Date:  2009-01-13       Impact factor: 4.130

7.  Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.

Authors:  A D Norden; G S Young; K Setayesh; A Muzikansky; R Klufas; G L Ross; A S Ciampa; L G Ebbeling; B Levy; J Drappatz; S Kesari; P Y Wen
Journal:  Neurology       Date:  2008-03-04       Impact factor: 9.910

  7 in total
  3 in total

Review 1.  Adult brainstem gliomas.

Authors:  German Reyes-Botero; Karima Mokhtari; Nadine Martin-Duverneuil; Jean-Yves Delattre; Florence Laigle-Donadey
Journal:  Oncologist       Date:  2012-03-01

2.  Treatment of adult brainstem glioma with combined antiangiogenic therapy: a case report and literature review.

Authors:  Dongdong Yu; Guang Han; Huali Liu; Likun Gao; Vivek Verma
Journal:  Onco Targets Ther       Date:  2019-02-18       Impact factor: 4.147

3.  Retrospective analysis of 104 histologically proven adult brainstem gliomas: clinical symptoms, therapeutic approaches and prognostic factors.

Authors:  Thomas Reithmeier; Aanyo Kuzeawu; Bettina Hentschel; Markus Loeffler; Michael Trippel; Guido Nikkhah
Journal:  BMC Cancer       Date:  2014-02-21       Impact factor: 4.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.